Immunicum AB Publishes the Annual Report for 2016

GOTHENBURG, Sweden, March 17, 2017 – Immunicum AB (publ; First North Premier: IMMU.ST) a biopharmaceutical company advancing a novel immuno-oncology treatment against a range of solid tumors, today announced that its Annual Report for July-December 2016 is now available in Swedish to read and to download on the company’s website, The English language version of the Annual Report will be available on the Immunicum website in the coming days.

The Annual Report will be sent by regular mail to shareholders and other interested parties upon special request. For further information, please contact the company by telephone +46 (0) 31 41 50 52 or e-mail,

About Immunicum AB (publ)
Immunicum AB (First North Premier: IMMU.ST) is a clinical stage company developing novel immuno-oncology therapies against a range of solid tumors. The Company’s lead compound, INTUVAX® is currently being evaluated in clinical trials for the treatment of kidney cancer, liver cancer and gastrointestinal stromal tumors. INTUVAX® was designed to combine the best of two worlds: a cost-effective cell-based (allogeneic) and off-the-shelf therapy that is capable of triggering a highly personalized and potentially long-lasting immune response against tumor cells throughout the body.

For more information, please contact:
Carlos de Sousa, CEO, Immunicum
Ph: +46 (0) 31 41 50 52

Media Contact
MacDougall Biomedical Communications
Gretchen Schweitzer or Stephanie May
Ph: +49 89 2424 3494 or + 49 172 861 8540

The Company’s Certified Adviser is Redeye AB
Ph: + 46 (0) 8 545 013 31

The information in this press release is disclosed pursuant to the Securities Markets Act. The information was released for public disclosure through the agency of the company’s contact person on March 17, 2017 at 8.00 am CET

Keep reading

Immunicum AB Announces Enrollment of First Patient in Phase I/II GIST Trial Following Study Protocol Amendment